SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?


To: rkrw who wrote (777)8/2/2004 11:16:09 PM
From: Biomaven  Respond to of 12215
 
I'd have to guess that SGP would be first in line for this drug.

I think it's too rich and too risky for SEPR at this stage - RIGL is talking about trials with several thousand people needed for approval. With a novel mechanism of action and an extremely high safety bar this isn't a risk-free program.

It's intriguing to wonder to what extent this mechanism can be extended to asthma.

Peter